![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
De Committee for Medicinal Products for Human Use (CHMP) heeft een aantal uitbreidingen van geneesmiddelindicaties goedgekeurd.
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug in the treatment of moderately to severely active ulcerative colitis (UC)...
Novartis’ Lucentis secures European approval for infants with rare eye disease
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European Commission earlier than expected in the treatment of preterm infants...
FDA approves first drug to treat patients with rare lung condition
The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or...
Mobile apps improve atrial fibrillation detection rates in a low-risk population
A new study has shown that mobile health (mHealth) devices are able to screen for the common cardiac disorder called atrial fibrillation (AF).
How to Develop a Content Strategy: Start With These 3 Questions
If your content doesn’t connect with an audience, success isn’t an option. But to get the audience, you first must answer these three essential questions. And use these resources to create an effective content marketing...
Old school en new school marketing hebben elkaar nodig
Marketing is een stuk spannender geworden dankzij de innovatieve technieken en grote hoeveelheden data die vandaag de dag beschikbaar zijn. Hierdoor ontstaan nieuwe mogelijkheden maar ook valkuilen, signaleert marketeer...
Got a Plan? Content Marketing Success Demands It
Not all of us control our brand’s content strategy. Our job is to develop the tactical plan – policies, processes, resources, and task-related decisions. Read on for a handy tutorial with the resources to make...
Meet niet je conversiepercentage, maar de conversiestappen
Is conversiepercentage voor jou een KPI? De vraag is of dat wel verstandig is, aangezien het erg op de korte termijn gericht is én je er weinig inzichten uit kunt halen voor verbeterstappen. Daarvoor kun je beter de...
‘Kunstmatig blad’ produceert voor het eerst medicijnen met zonlicht
Medicijnen goedkoop en overal kunnen produceren, met zonlicht als energiebron. Die realiteit is dichterbij dan ooit nu chemici van de TU Eindhoven een ‘mini-reactor’ presenteren die, vergelijkbaar met bladeren in de...
Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis
Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at Phase 3 when used in combination with phosphate binders in the treatment...
Ofatumumab Bests Teriflunomide in Head-to-Head MS Trials
Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis), a CD20-directed cytolytic monoclonal antibody, resulted in a highly significant and clinically meaningful reduction...
7 AI-tools die je als marketeer kunt gebruiken
Kunstmatige intelligentie is hipper dan ooit. Kijk alleen maar naar de enorme bedragen die erin omgaan. Microsoft pompt 1 miljard dollar in een samenwerking met het bedrijf OpenAI. De Europese Unie wil jaarlijks 20...
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the tyrosine kinase inhibitor Inlyta (axitinib) in the first-line treatment of advanced renal...
Cancer drugs’ share of new FDA approvals doubled this decade thanks to smarter R&D: report
Pursuing novel mechanisms for treating cancer and validating them with clinical trials has paid off for drug developers, especially as the FDA is speeding up approvals of new treatments for unmet medical needs, a Tufts...
Content en communicatie: dé trends & tips voor de tweede helft van 2019
We zijn natuurlijk al flink op weg in 2019, maar ‘na de zomer’ voelt toch altijd een beetje als de tweede helft van het jaar. Heb jij al scherp waarop jij je deze laatste maanden gaat focussen? Of is alles weggeëbd...
Get a Refresh on the What, Why, Where, and How of Content Marketing
It’s always a good time to revisit the fundamentals of successful content marketing. The guide is a nice refresh of the core content marketing elements – and helpful resources – essential to a successful program...
Novartis phase III ASCLEPIOS I & II studies of ofatumumab versus Aubagio to treat relapsing forms MS meets primary endpoints
Novartis announced positive results for ofatumumab (OMB157) from the phase III ASCLEPIOS I and II studies. In both head─to─head studies, ofatumumab demonstrated superiority over Aubagio (teriflunomide) in patients
